2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Bart Spronck; Dimitrios Terentes-Printzios; Alberto P Avolio; Pierre Boutouyrie; Andrea Guala; Ana Jerončić; Stéphane Laurent; Eduardo C D Barbosa; Johannes Baulmann; Chen-Huan Chen; Julio A Chirinos; Stella S Daskalopoulou; Alun D Hughes; Azra Mahmud; Christopher C. Mayer; Jeong Bae Park; Gary L Pierce; Aletta E Schutte; Elaine M Urbina; Ian B Wilkinson; Patrick Segers; James E Sharman; Isabella Tan; Charalambos Vlachopoulos; Thomas Weber; Elisabetta Bianchini; Rosa Maria Bruno

doi:10.1161/HYPERTENSIONAHA.123.21618

2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Bart Spronck
, Dimitrios Terentes-Printzios
, Alberto P Avolio
, Pierre Boutouyrie
, Andrea Guala
, Ana Jerončić
, Stéphane Laurent
, Eduardo C D Barbosa
, Johannes Baulmann
, Chen-Huan Chen
, Julio A Chirinos
, Stella S Daskalopoulou
, Alun D Hughes
, Azra Mahmud
, Christopher C. Mayer
, Jeong Bae Park
, Gary L Pierce
, Aletta E Schutte
, Elaine M Urbina
, Ian B Wilkinson

Patrick Segers, James E Sharman, Isabella Tan, Charalambos Vlachopoulos, Thomas Weber, Elisabetta Bianchini, Rosa Maria Bruno,

Medical Signal Analysis

Cincinnati Children's Hospital Medical Center
University of Cincinnati
Cardiology Department, Klinikum Wels-Grieskirchen
Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases
1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens
Service de Pharmacologie et Hypertension, AP-HP, Georges-Pompidou European Hospital (Hôpital Européen Georges Pompidou)
Vall d’Hebron Institut de Recerca
CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain
Laboratory of Vascular Aging and Cardiovascular Prevention, Department of Research in Biomedicine and Health, University of Split School of Medicine, Croatia (A.J.)
Feevale University, Santa Casa Hospital, Porto Alegre, Brazil (E.C.D.B)
Praxis Dres. Gille/Baulmann
Division of Cardiology, Department of Internal Medicine, MedUni Graz
Cardiovascular Division, University of Pennsylvania Perelman School of Medicine and Hospital of the University of Pennsylvania, Philadelphia, USA (J.A.C.)
Department of Medicine, Research Institute McGill University Health Centre, McGill University
Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science, University College London
Department of Internal Medicine, Pharmacology and Clinical Research, Shalamar Medical and Dental College, Lahore, Pakistan (A.M.)
JB Lab and Clinic, Department of Precision Medicine and Biostatistics, Wonju College of Medicine, Yonsei University, Seoul, Republic of Korea (J.B.P.)
Department of Health and Human Physiology, University of Iowa
School of Population Health, University of New South Wales, Sydney
The George Institute for Global Health
Division of Experimental Medicine and Immunotherapeutics, University of Cambridge
IBiTech-BioMMedA, Ghent University, Belgium
Menzies Institute for Medical Research, University of Tasmania
Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney
Institute of Clinical Physiology, CNR (National Research Council)
Paris Cardiovascular Research Center (PARCC)
Service of Pharmacology and Hypertension, Assistance Publique–Hôpitaux de Paris (AP–HP), European Hospital Georges Pompidou, Paris
Université Paris Cité

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations.

METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices.

RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice.

CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

Original language	English
Pages (from-to)	183-192
Number of pages	10
Journal	Hypertension
Volume	81
Issue number	1
Early online date	17 Nov 2023
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.123.21618
Publication status	Published - Jan 2024

Research Field

Medical Signal Analysis

Keywords

Legged locomotion
Global navigation satellite system
Correlation
Telemedicine
Measurement uncertainty
Cardiovascular diseases
Reliability
aorta
cardiovascular diseases
guideline
pulse wave analysis
vascular stiffness

Access to Document

10.1161/HYPERTENSIONAHA.123.21618Licence: CC BY

Cite this

Spronck, B., Terentes-Printzios, D., Avolio, A. P., Boutouyrie, P., Guala, A., Jerončić, A., Laurent, S., Barbosa, E. C. D., Baulmann, J., Chen, C.-H., Chirinos, J. A., Daskalopoulou, S. S., Hughes, A. D., Mahmud, A., Mayer, C. C., Park, J. B., Pierce, G. L., Schutte, A. E., Urbina, E. M. (2024). 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices. Hypertension, 81(1), 183-192. https://doi.org/10.1161/HYPERTENSIONAHA.123.21618

@article{3610eb1ef72e4d1c939a68cd40a68cb6,

title = "2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices",

abstract = "BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations.METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices.RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice.CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.",

keywords = "Legged locomotion, Global navigation satellite system, Correlation, Telemedicine, Measurement uncertainty, Cardiovascular diseases, Reliability, aorta, cardiovascular diseases, guideline, pulse wave analysis, vascular stiffness",

author = "Bart Spronck and Dimitrios Terentes-Printzios and Avolio, \{Alberto P\} and Pierre Boutouyrie and Andrea Guala and Ana Jeron{\v c}i{\'c} and St{\'e}phane Laurent and Barbosa, \{Eduardo C D\} and Johannes Baulmann and Chen-Huan Chen and Chirinos, \{Julio A\} and Daskalopoulou, \{Stella S\} and Hughes, \{Alun D\} and Azra Mahmud and Mayer, \{Christopher C.\} and Park, \{Jeong Bae\} and Pierce, \{Gary L\} and Schutte, \{Aletta E\} and Urbina, \{Elaine M\} and Wilkinson, \{Ian B\} and Patrick Segers and Sharman, \{James E\} and Isabella Tan and Charalambos Vlachopoulos and Thomas Weber and Elisabetta Bianchini and Bruno, \{Rosa Maria\}",

note = "{\textcopyright} 2023 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. (CC-BY)",

year = "2024",

month = jan,

doi = "10.1161/HYPERTENSIONAHA.123.21618",

language = "English",

volume = "81",

pages = "183--192",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

Spronck, B, Terentes-Printzios, D, Avolio, AP, Boutouyrie, P, Guala, A, Jerončić, A, Laurent, S, Barbosa, ECD, Baulmann, J, Chen, C-H, Chirinos, JA, Daskalopoulou, SS, Hughes, AD, Mahmud, A, Mayer, CC, Park, JB, Pierce, GL, Schutte, AE, Urbina, EM, Wilkinson, IB, Segers, P, Sharman, JE, Tan, I, Vlachopoulos, C, Weber, T, Bianchini, E, Bruno, RM 2024, '2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices', Hypertension, vol. 81, no. 1, pp. 183-192. https://doi.org/10.1161/HYPERTENSIONAHA.123.21618

TY - JOUR

T1 - 2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

AU - Spronck, Bart

AU - Terentes-Printzios, Dimitrios

AU - Avolio, Alberto P

AU - Boutouyrie, Pierre

AU - Guala, Andrea

AU - Jerončić, Ana

AU - Laurent, Stéphane

AU - Barbosa, Eduardo C D

AU - Baulmann, Johannes

AU - Chen, Chen-Huan

AU - Chirinos, Julio A

AU - Daskalopoulou, Stella S

AU - Hughes, Alun D

AU - Mahmud, Azra

AU - Mayer, Christopher C.

AU - Park, Jeong Bae

AU - Pierce, Gary L

AU - Schutte, Aletta E

AU - Urbina, Elaine M

AU - Wilkinson, Ian B

AU - Segers, Patrick

AU - Sharman, James E

AU - Tan, Isabella

AU - Vlachopoulos, Charalambos

AU - Weber, Thomas

AU - Bianchini, Elisabetta

AU - Bruno, Rosa Maria

N1 - © 2023 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. (CC-BY)

PY - 2024/1

Y1 - 2024/1

N2 - BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations.METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices.RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice.CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

AB - BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations.METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices.RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice.CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

KW - Legged locomotion

KW - Global navigation satellite system

KW - Correlation

KW - Telemedicine

KW - Measurement uncertainty

KW - Cardiovascular diseases

KW - Reliability

KW - aorta

KW - cardiovascular diseases

KW - guideline

KW - pulse wave analysis

KW - vascular stiffness

UR - https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.123.21618

U2 - 10.1161/HYPERTENSIONAHA.123.21618

DO - 10.1161/HYPERTENSIONAHA.123.21618

M3 - Article

C2 - 37975229

SN - 0194-911X

VL - 81

SP - 183

EP - 192

JO - Hypertension

JF - Hypertension

IS - 1

ER -

2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Abstract

Research Field

Keywords

Access to Document

Other files and links

Fingerprint

2024 Best of Hypertension - Clinical Science Category

Cite this

2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Abstract

Research Field

Keywords

Access to Document

Other files and links

Fingerprint

Prizes

2024 Best of Hypertension - Clinical Science Category

Cite this